2 2 Dermatology and Oncology Consulting Ltd 12074862 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is providing medical consultancy services Digita Accounts Production Advanced 6.30.9574.0 true true 12074862 2023-07-01 2024-06-30 12074862 2024-06-30 12074862 bus:OrdinaryShareClass1 2024-06-30 12074862 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 12074862 core:FurnitureFittingsToolsEquipment 2024-06-30 12074862 core:MotorVehicles 2024-06-30 12074862 bus:SmallEntities 2023-07-01 2024-06-30 12074862 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 12074862 bus:FilletedAccounts 2023-07-01 2024-06-30 12074862 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 12074862 bus:RegisteredOffice 2023-07-01 2024-06-30 12074862 bus:Director1 2023-07-01 2024-06-30 12074862 bus:Director2 2023-07-01 2024-06-30 12074862 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 12074862 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 12074862 bus:Agent1 2023-07-01 2024-06-30 12074862 core:FurnitureFittingsToolsEquipment 2023-07-01 2024-06-30 12074862 core:MotorVehicles 2023-07-01 2024-06-30 12074862 core:OfficeEquipment 2023-07-01 2024-06-30 12074862 countries:England 2023-07-01 2024-06-30 12074862 2023-06-30 12074862 core:FurnitureFittingsToolsEquipment 2023-06-30 12074862 core:MotorVehicles 2023-06-30 12074862 2022-07-01 2023-06-30 12074862 2023-06-30 12074862 bus:OrdinaryShareClass1 2023-06-30 12074862 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 12074862 core:FurnitureFittingsToolsEquipment 2023-06-30 12074862 core:MotorVehicles 2023-06-30 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 12074862

Dermatology and Oncology Consulting Ltd

Unaudited Filleted Financial Statements

for the Year Ended 30 June 2024

 

Dermatology and Oncology Consulting Ltd

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3

Notes to the Unaudited Financial Statements

4 to 6

 

Dermatology and Oncology Consulting Ltd

Company Information

Directors

Dr AE Ring

Dr EJ Topham

Registered office

Cawley Place
15 Cawley Road
Chichester
West Sussex
PO19 1UZ

Accountants

Blue Spire Limited Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Dermatology and Oncology Consulting Ltd
for the Year Ended 30 June 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Dermatology and Oncology Consulting Ltd for the year ended 30 June 2024 as set out on pages 3 to 6 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Dermatology and Oncology Consulting Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Dermatology and Oncology Consulting Ltd and state those matters that we have agreed to state to the Board of Directors of Dermatology and Oncology Consulting Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Dermatology and Oncology Consulting Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Dermatology and Oncology Consulting Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Dermatology and Oncology Consulting Ltd. You consider that Dermatology and Oncology Consulting Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Dermatology and Oncology Consulting Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
PO19 1SY

10 March 2025

 

Dermatology and Oncology Consulting Ltd

(Registration number: 12074862)
Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

31,015

41,955

Current assets

 

Cash at bank and in hand

 

300,566

194,223

Creditors: Amounts falling due within one year

6

(33,171)

(11,759)

Net current assets

 

267,395

182,464

Net assets

 

298,410

224,419

Capital and reserves

 

Called up share capital

7

200

200

Retained earnings

298,210

224,219

Shareholders' funds

 

298,410

224,419

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 10 March 2025 and signed on its behalf by:
 

.........................................
Dr EJ Topham
Director

 

Dermatology and Oncology Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Cawley Place
15 Cawley Road
Chichester
West Sussex
PO19 1UZ

These financial statements were authorised for issue by the Board on 10 March 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

4 years straight line

Motor vehciles

25% reducing balance

 

Dermatology and Oncology Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

 

Dermatology and Oncology Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 July 2023

2,401

54,455

56,856

At 30 June 2024

2,401

54,455

56,856

Depreciation

At 1 July 2023

1,288

13,613

14,901

Charge for the year

730

10,210

10,940

At 30 June 2024

2,018

23,823

25,841

Carrying amount

At 30 June 2024

383

30,632

31,015

At 30 June 2023

1,113

40,842

41,955

5

Debtors

Current

2024
£

2023
£

 

-

-

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

26,600

6,510

Accruals and deferred income

1,320

1,230

Other creditors

5,251

4,019

33,171

11,759

7

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

200

200

200

200